

## Special Issue

# Blood Microrheology in Health and Disease

### Message from the Guest Editor

The red blood cells (RBCs) are a crucial factor affecting normal blood microfluidics since the plasma flows in a completely different way without them. Under specific conditions, and with the contribution of other blood cells and proteins, the aggregability increases to such a degree that local microthrombi are formed. In addition, hemodynamics plays an important role since the behavior of blood changes at very low or high shear rates and stresses. Some of the RBC properties that affect the microrheology of blood are deformability, aggregability, membrane viscosity, cytoplasmic viscosity, and endurance to shear stress. Some of the related pathological conditions are microthrombosis, sickle cell disease, and related retinopathy and nephropathy. The scope of this Special Issue is to accept original research and reviews on the latest developments on blood cell properties and biomarkers related to blood microfluidics, and/or on how blood microfluidics may change under the influence of disease or drugs inside microvessels in vivo or in vitro.

### Guest Editor

Dr. Aristotle G. Koutsiaris

MIBI Laboratory, Faculty of Medicine, University of Thessaly, 41500 Larissa, Greece

### Deadline for manuscript submissions

closed (31 July 2023)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/161268](https://mdpi.com/si/161268)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).